Abstract:Peiqiu Zhu, 1 Weiwei Deng 2 1 Department of Dermatology and Venereology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, People's Republic of China Correspondence: Weiwei Deng, Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, People's Republic of China, Tel +86 15622165048, Email Background: Systemic sclerosis represents a persistent autoimmune disorder marked with fibrosis affecting both skin and other organs, which leads to a diminished quality of life and increased mortality. The affected skin provides a valuable opportunity to explore the pathogenesis of systemic sclerosis. Nevertheless, the roles of various cell populations within scleroderma remain intricate. Methods: We conducted a comprehensive reanalysis of recently published single-cell RNA-sequencing data from skin tissue cells in scleroderma. Through the utilization of Seurat, irGSEA, AUCell packages, and WGCNA analysis, we aimed to unveil crucial genes associated with the disease's etiological factors. Our investigation involved the characterization of heterogeneous pathway activities in both healthy and SSc-affected skin. Furthermore, we employed immunofluorescence techniques to validate the expression patterns of hub genes and differentially expressed genes. Results: The Endothelial-to-Mesenchymal Transition (EndMT) pathway was upregulated in SSc skin. Notably, the M4 module within Endothelial cell subpopulation 1 exhibited a strong association with EndMT. Furthermore, we identified three overexpressed genes ( APLNR , I NS-IGF2, RGCC ) that demonstrated a significant correlation with EndMT. Importantly, their expression levels were markedly higher in skin of individuals with SSc when compared to healthy controls. Conclusion: APLNR, INS-IGF2 and RGCC serve as potential key players in the pathogenesis of SSc skin through EndMT-dependent mechanisms. Keywords: systemic sclerosis skin, single cell RNA-sequencing analysis, the Endothelial to Mesencchymal Transition, EndMT, APLNR , INS-IGF2 , RGCC As a sort of uncommon connective tissue disorder, scleroderma is distinguished by cutaneous sclerosis and variable systemic involvement. 1 There are 2 main forms of systemic sclerosis(SSc): localized scleroderma (LS), also known as limited cutaneous SSc, and diffuse SSc. 2 It is currently believed that patients who develop SSc have an underlying genetic predisposition to these conditions and are subsequently exposed to environmental factors that initiate inflammatory and fibrotic processes. 3 The common clinical manifestations of SSc encompass skin fibrosis, digital vascular ulcers, arrhythmias in involvement with the cardiovascular system, pulmonary fibrosis, pulmonary artery hypertension, fibrotic changes in the gastrointestinal tract, endothelial cell injury in the kidneys, and even hand (finger) flexion contractures. 4 Evaluation of sclerotic skin reveals thickened and homogenized collagen bundles in both superficial and middle dermis. 5 Qualitative SSc nailfold capillary number has been developed to accurately determine capillary absolute number and density from nail-fold video capillaroscopy images, which has been successfully validated in patients diagnosed with systemic sclerosis (SSc). 6 Etiological factors trigger the activation of keratinocytes, T cells, and the production of various components that contribute to fibrosis. These factors induce fibroblast proliferation through toll-like receptor 4 (TLR-4) by enhancing the activity of transforming growth factor β (TGF-β). 7 A preliminary study, albeit with a small number of cells and samples, suggested that inhibiting TGF-β1 signaling might be one of the most promising approaches to treat skin fibrosis in scleroderma. 8 In recent years, while the role of the TGF-β family in the pathogenesis of LS has been confirmed, the signal pathways and molecular process involved are too complex to fully elucidate. Consequently, investigating the molecular mechanisms within different types of cells, cytokines, and extracellular matrix (ECM) components can help uncover what lies beneath the surface. Several studies have provided evidence supporting the involvement of endothelial cells (EC) in endothelial-to-mesenchymal transition (EndMT), a recently acknowledged form of cellular trans-differentiation. Involved in crucial embryonic development processes, EndMT assumes a significant role in the development of various genetically determined and acquired human diseases, including -Abstract Truncated-

Pathogenesis and staging of scleroderma

Pathophysiology of systemic sclerosis (scleroderma)

Scleroderma and scleroderma-like syndromes

Current Concepts on the Pathogenesis of Systemic Sclerosis

Systemic sclerosis in adults. Part I: Clinical features and pathogenesis

A Multidisciplinary Approach as A Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario

Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis

Scleritis: Immunopathogenesis and molecular basis for therapy

Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review

Molecular Mechanisms, Pathogenetic Role and Therapeutic Opportunities

Pathogenesis of systemic sclerosis-current concept and emerging treatments

Scleroderma therapy: clinical overview of current trends and future perspective

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes

The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement

Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course

Single-Cell RNA-Sequencing Analyses Identify APLNR, INS-IGF2, RGCC Genes May Be Involved in the Pathogenesis of Systemic Sclerosis Skin

Systemische Sklerose

[Autoimmune and inflammatory pathologies associated with systemic scleroderma: Clinical, serological and prognostic profiles. Bi-centric retrospective series in the PACA region]

Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review

What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?

Progressive loss of lymphatic vessels in skin of patients with systemic sclerosis